This stock is in 건강관리: revenue rank 127 of 287, share 0.1%.
127 / 2870.1%revenue share
Sinil Pharmaceutical
A012790 · KOSDAQ₩5,950+2.23%
2026-08-25 closeSinil Pharmaceutical — pricey right now, or cheap? And what signals are flashing today?
The grade and valuation bands are below — free to read.
Loading chart…
Close
AI Insight
Why these signals fired — only backtest-proven edge, told honestly
New high + volume — the real recordrecord · not a prediction
Not this one stock, but every new-high-plus-volume pick we actually published (Korea market). When this stock flashes the signal, it is treated by the same rule.(as of 2026-08-25)
Last 30 sessions
402 picks
Next-day win rate
51.6%
Avg next-day
-0.06%
vs market
-0.24%p
Beat the market on 45.3% of picks (each pick vs its own day’s market average).
Recent publish days (next-day win rate)
08-23 60%08-21 36.4%08-20 44.4%08-19 0%08-18 27.3%08-14 23.1%08-13 41.7%08-12 70%08-11 77.8%08-10 22.2%08-07 61.5%08-06 27.3%
This stock has not flashed this signal recently — the record above is the signal’s own, not this stock’s.
Entry is the latest close at publish time; next-day is the following close. “Market” is the equal-weighted average of every stock in the same market that day; delisted names are excluded from both. Fees, taxes and slippage are not included. An observed record over a short window, not a pre-registered backtest. Not investment advice.
Trade plan
Decide the exit before you enter. Set what you are willing to lose first, and the share count follows — so you know the worst case before you buy.
Fill entry, stop, account size and risk percent to get a share count. The stop must sit below the entry.
This is a calculator, not advice, and it does not promise any outcome. You choose the stop and target — the button values (ATR, recent low/high) are observations from past prices. Actual fills depend on the order book and liquidity.
Valuation Grades
Relative to 292 건강관리 peers · not investment advice
A+
Overall: 건강관리 22/292 · top 7%
Factor composite · relative position in sector
Valuation in its own history
PER 4.99 · PBR 0.49 — own history (2000-01~) percentiles 99/100 · 96/100
PER99/100
PBR96/100
Higher indicates lower valuation relative to its history (based on earnings and book yields).
Earnings percentiles can fluctuate for cyclical companies (including loss periods), so the book basis is shown alongside. Companies with large share buybacks can have structurally high PBR. Factual information, not investment advice.
Annual dividend
Split-adjusted annual DPS history and available grade axes
Paid 3 consecutive years · Raised 2 consecutive years · Yield 3.19% (based on 2025 payment of 190원)
Per-share amount adjusted for splits and capital reductions · Factual information, not investment advice.
Financial safety
Reference indicatorAs of 2024Safe zoneFinancial-metric reference signal
Altman Z'' zoneZ'' 13.74
Distress
Grey
Safe
- Altman Z''
- 13.74
- Beneish M-Score
- -2.86
- Sloan accrual
- -5.06%
No statistical flag
부실·조작 위험을 나타내는 사실 지표입니다. 투자 조언이 아니며, 검증 전이라 참고용입니다.
Factual information, not investment advice.
Earnings quality · Piotroski F-Score
5/9Moderate
Piotroski measures year-over-year financial improvement, not absolute quality.
Financial improvement score5/9
Profitability
- Positive ROAPass
- Positive OCFPass
- Improving ΔROANot passed
- Accruals (OCF > net income)Pass
Leverage & liquidity
- Lower debtNot passed
- Higher current ratioNot passed
- No new sharesPass
Efficiency
- Higher gross marginPass
- Higher asset turnoverNot passed
Calculation note: F7(신주)은 equity/asset 유지로 근사
Already-stable companies may score lower when year-over-year improvement is limited.
Factual information, not investment advice.
Industry structure
KRAs of 2026-08-25건강관리
Who dominates this industry?
- 1삼성바이오로직스7.3%
- 2셀트리온5.7%
- 3녹십자홀딩스3.5%
- 4유한양행3.3%
- 5대웅3.1%
- 6신일제약0.1%
Concentration
DistributedCR3 16.6%HHI and CR3 are separate industrial-organization facts; they are not the polarization verdict.
Polarization
Winner-take-all deepeningConsistentPolarization measures industry gaps and structure, not valuation, forecast, or investment advice.
Margin lens
- IQR%p
- 31.61
- Direction
- 확대
- Level
- 넓음
- Years
- 7
Value lens
- P90/P10
- 14
- Median P/B
- 1.47
- Level
- 넓음
- n
- 263
Survivorship note: 현재 산업 멤버십을 과거 연도에 소급 적용 — 과거 진입·퇴출 기업 미반영(복원 불가)
Factual information, not investment advice.
Risk sensitivity — adverse assumptions
Metric changes under stated assumptions; not a forecast or investment advice.
Base metrics
- Operating margin
- 17.1%
- Interest coverage
- 565.6x
- Return on equity (ROE)
- 9.8%
Operating margin −5pp
TolerableInterest coverageBase 565.6x adverse case 399.7x
Return on equity (ROE)Base 9.8% adverse case 7.3%
Revenue −15%
TolerableInterest coverageBase 565.6x adverse case 480.7x
Return on equity (ROE)Base 9.8% adverse case 8.8%
Interest rate +2pp
TolerableInterest coverageBase 565.6x adverse case 36.8x
Return on equity (ROE)Base 9.8% adverse case 10.1%
Interest coverage limit
Current margin 17ppInterest coverage limit at an operating margin of 0%
Interest expense coverage threshold
Key suppliers · Annual report
Annual reportDART · 2026-03-18Suppliers disclosed by the company in its 2026-03-18 annual report.
Purchase amount
KRW 100m- HClKRW 337.8B
- SarpogrelateKRW 337.8B
Suppliers without disclosed amount
IbuprofenDexibuprofen
Financials at a glance
Sinil Pharmaceutical's latest results and balance sheet. The bars track the last three periods.
Connections
AI-extracted related companies · for reference
Competitors
동아에스티Price comovement r=0.56 (1 year)유한양행Price comovement r=0.45 (1 year)대웅제약Price comovement r=0.40 (1 year)종근당Price comovement r=0.45 (1 year)보령Price comovement r=0.63 (1 year)한미약품Price comovement r=0.36 (1 year)GC녹십자일동제약Price comovement r=0.20 (1 year)삼성바이오로직스Price comovement r=0.29 (1 year)셀트리온Price comovement r=0.40 (1 year)
Recent filings
Sinil Pharmaceutical's latest filings on Korea's DART. Open a headline for a reference summary and the original.
Source: DART (Korea electronic disclosure)
Like these rules? Run them automatically.
Quantus turns rules like these into backtests and automated trading — same team, free to start.
Quantus Signal · live data · not investment advice · Privacy Policy